PubMed
A synthetic fragment of human growth hormone promotes lipid mobilization
Heffernan MA, Thorburn AW, Fam B, et al. Int J Obes Relat Metab Disord. 2001
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 52% · Mixed 36% · Unfavorable overall 12%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 10–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 27 days · Based on 495 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 52% · Mixed 30% · Unfavorable overall 18%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.025–5 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 62% said they felt similar to their last entry, 38% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 33 days · Based on 39 repeat reporters
Published sources linked on the AOD-9604 and Clomiphene wiki pages.
PubMed
Heffernan MA, Thorburn AW, Fam B, et al. Int J Obes Relat Metab Disord. 2001
PubMed
Ng FM, Sun J, Sharma L, et al. Osteoarthritis Cartilage. 2010
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Heffernan MA, Thorburn AW, Fam B, et al. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2001
PubMed
Heffernan M, Summers RJ, Thorburn A, et al. Endocrinology. 2001
PubMed
Moskovic DJ, Katz DJ, Akhavan A, et al. Curr Urol Rep. 2012
PubMed
Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Fertility and sterility. 2014
PubMed
Conforti A, Carbone L, Di Girolamo R, et al. Fertility and sterility. 2025